India Pharma Outlook Team | Monday, 01 December 2025
RPG Life Sciences is stepping into India’s growing GLP-1 market — targeting obesity and diabetes — and laying the groundwork for a bold expansion that could reshape its future.
The company has outlined an ambition to reach Rs 2,500 crore turnover by 2030, driven by a push into specialty formulations, active pharmaceutical ingredients (APIs), and generics.
At the heart of this strategy is a shift away from mass-market therapies toward super-specialty segments like nephrology, rheumatology, gastroenterology, dermatology, and niche cardiology. This focus on clinically complex, long-term therapies supports more stable branding and deeper market penetration.
Also Read: How Pharma Authentication Tech Enhances ROI and Safety
For the GLP-1 segment, RPG Life Sciences plans to rely on partnership-led launches once patents expire, since peptide manufacturing remains limited in India. The company believes generic versions could come at 50–70% lower prices than branded innovator drugs — a change that can widen access and trigger market shift.
“We have created a strategic vision built around five pillars, with building big, scalable brands at the core,” said Ashok Nair, Managing Director, RPG Life Sciences.
On the growth side, RPG reported ?582.1 crore revenue in FY25, up 13.5% year-on-year, and Rs 181.7 crore in Q2 FY26, showing continued momentum.
Another dimension of the strategy: expand API capacity through selective acquisitions, especially focusing on immunosuppressants — which also supports its specialty-drug ambitions. For global reach, the company is considering acquiring USFDA-approved manufacturing plants to break into the US market within the next few years, a faster route than building capacity from scratch.
With India’s API industry expected to grow strongly through 2030, RPG’s integrated push into formulations, generics and API manufacturing puts it squarely in line with broader industry trends.
